“At Synexa, patient-centricity is at the heart of everything we do. Gyrolab® stands out as a vital tool, as it offers nanoliter-scale precision and an automated workflow—both of which minimize patient burden while accelerating and enhancing the efficiency of our results.”

Synexa Life Sciences is a global leader in biomarker and bioanalytical services, with a team of over 200 experts across five laboratory locations—Cape Town, London, Manchester, and Turku (Finland). Since acquiring Syrinx Bioanalytics in 2022, Synexa has continued to leverage advanced technologies like Gyrolab® to deliver high-quality bioanalytical solutions for its global biopharma partners.

Synexa_Logo_Full Colour

The low sample consumption, high sensitivity, and broad dynamic of Gyrolab platform range provide a critical edge in preclinical and clinical studies, enabling Synexa to tackle complex challenges with precision and efficiency. The Synexa team in Turku, with its deep expertise in high-performance bioanalytical technologies, has been at the forefront of leveraging Gyrolab platform’s capabilities. The platform’s low sample consumption, high sensitivity, and broad dynamic range make it an invaluable tool for preclinical and clinical studies, particularly where sample volume is limited.

Jordyn van Teylingen, Global Head of Bioanalysis & Soluble Biomarkers at Synexa, explains:

"At Synexa, patient-centricity is at the heart of everything we do. Gyrolab® stands out as a vital tool, as it offers nanoliter-scale precision and an automated workflow—both of which minimize patient burden while accelerating and enhancing the efficiency of our results."

Synexa and Gyrolab have built a strong partnership over the years, driven by a shared commitment to innovation and excellence.

"Gyrolab is a very reliable partner, and we have received excellent scientific support" says Jordyn van Teylingen.

Find out more at www.synexagroup.com